Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Synaptogenix is a biopharmaceutical company focused on developing therapies for neurodegenerative and cognitive disorders, primarily Alzheimer's disease. Its core platform involves activating Protein Kinase C epsilon (PKCε) using Bryostatin-1, a natural product and synthetic derivatives, to promote synaptic regeneration and neuronal protection. The company advances drug candidates through preclinical and clinical testing, leveraging licensed technologies and strategic collaborations to address unmet medical needs in neurodegeneration.
This description was generated via AI from an annual report. Updated about 1 year ago.